Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A University of Oxford team has been awarded a grant to study one of the major unsolved questions about asthma – why women are more likely to have it than men and why they are twice as likely to die from it.

Woman using asthma inhaler

Bioinformatician Dr Emanuele Marchi has received £98,000 from the national charity Asthma + Lung UK to analyse data that may shed light on why more women than men have asthma, why they experience significantly higher numbers of asthma attacks and why they are more likely to end up in hospital as a result.

Emanuele said: “This aspect of asthma – which disproportionately affects the life of women – has not been adequately studied, so we do not understand the biological factors that cause asthma to affect women differently. If we can understand this, we can look towards developing new treatments and a more personalised approach.”

The study team is supported by the NIHR Oxford Biomedical Research Centre (BRC).

Emanuele will examine data from 12 studies where samples were taken from the airways in the lungs, where the inflammation that causes asthma occurs. This data will be reanalysed with three questions in mind:

  • How does the inflammation of the airways in asthma differ between men and women, and how does this relate to hormone levels?
  • Which genes cause female forms of asthma?
  • Does the inflammation in women with asthma not respond as well to steroid treatment and why?

Dr Samantha Walker, Director of Research and Innovation at Asthma + Lung UK, said: “We don’t know why asthma is so much worse in women, so research like this is vital to work out how best to treat and prevent it. Currently, there isn’t enough research into why women are more likely to be hospitalised and die from asthma, as well as what treatments new and existing could help them.

“We’re delighted to be funding this work, which will help researchers understand the role of sex hormones in asthma and could help transform the lives of up to three million women with the condition in the UK, and the millions around the world. But much more investment is needed to prevent more lives being needlessly cut short.”

Victoria Sargent, aged 44 from North Oxfordshire, has taken part in asthma research, including a trial by the pharmaceuticals company Sanofi of its drug dupilumab, which is now used in the NHS to treat severe asthma.

Victoria has had asthma since she was 19, as a result of a chronic inflammatory disorder of the sinuses and lungs. Taking dupilumab, she says, has been a “life-changer”, and would not hesitate to take part in other clinical trials.

She welcomes the new study: “As a woman, I can only see this as a positive, thoughtful, future-facing move. Now that we know that asthma comes in many classifications and it’s either a symptom of another condition, as in my case, or the actual disease itself, maybe they’ll also find out that there are other factors, such as hormones, genetics or women’s physiology at play.

“The vast majority of medical studies don’t distinguish between men and women, and the male body is still thought of as the default. Men’s and women’s bodies are very different physiologically and if we’re not separating out our trials, then we are doing people a disservice by not recognising their different chemical balances and hormones. For me it’s the next logical step,” Victoria adds.

“Medicine should be preventative as much as possible. If we can treat asthma before it becomes too bad, and we know that women are more affected than men, that is going to help with managing medical resources down the line.”

The study’s Principal Investigator, Prof Timothy Hinks, Associate Professor of Respiratory Immunology at the University’s Nuffield Department of Medicine and a senior BRC respiratory researcher, said: “This work has the potential to define for the first time the changes underlying asthma specific to women. This will open new lines of enquiry for further scientific research. It may even allow us to identify new drug targets or new approaches to managing asthma.

“For our patients and their carers, increased understanding of the mechanisms of the disease will lead to an explanation for their lived experiences of asthma, and perhaps hope that in future specific and personalised treatments might be offered to them.”

Similar stories

Oxford’s RECOVERY trial team amongst MRC‘s Outstanding Team Impact prize finalists

The inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.

Constant genetic surveillance needed to counter multidrug-resistant malaria strains

Continual monitoring of genetic changes in parasite populations is a powerful tool for analysing malaria outbreaks and identifying emerging multidrug-resistant malaria strains, say researchers from NDM’s Mahidol-Oxford Tropical Medicine Research Unit (MORU).

Lancet study informs WHO guidelines for the treatment of malaria in pregnancy

The study from the Worldwide Antimalarial Resistance Network (WWARN) provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.